S55746 hydrochloride
CAS No. 1448525-91-4
S55746 hydrochloride( BCL201 | BCL-201 | S 55746 | S-55746 | Servier-1 )
Catalog No. M11922 CAS No. 1448525-91-4
S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 740 | Get Quote |
|
| 100MG | 1269 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameS55746 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionS55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
-
DescriptionS55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM, 70- 400 fold selectivity over BCL-XL, on significant binding to MCL-1 and BFL-1; potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM, exhibits a much weaker activity in H146 (IC50 1.7 μM), a BCL-XL-dependent cell line; concentration-dependently disrupts the BCL-2/BAX complex in RS4;11 cells, selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner; induces cell death in a panel of non-Hodgkin lymphoma cells; inhibits xenograft growth in RS4;11 and Toledo models.Blood Cancer Phase 1 Clinical.
-
In VitroS55746 (0-1 μM) potently and selectively induces cell death.S55746 selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner. Western Blot Analysis Cell Line:H146 and RS4;11 cell lines. Concentration:0, 0.1, 0.3 and 1 μM.Incubation Time:72 hours.Result:Potently induced RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM.
-
In VivoS55746 is a highly efficacious and well-tolerated (even at doses up to 300 mg/kg) orally active BCL-2 inhibitor . S55746 (20-100 mg/kg, p.o.) inhibits xenograft growth in RS4;11 and Toledo models time- and dose-dependently. Animal Model:Female SCID/beige mice implanted subcutaneously with 3×106 Toledo or RS4;11. Dosage:20, 50, 100 mg/kg. Administration:Oral gavage daily for 7 consecutive days.Result:Induced significant anti-tumor activity time- and dose-dependently.Animal Model:SCID/beige female mice with RS4;11 tumor xenografts.Dosage:25 and 100 mg/kg.Administration:Single oral gavage treatment.Result:Did not induce platelet loss in vivo at 25 and 100 mg/kg.
-
SynonymsBCL201 | BCL-201 | S 55746 | S-55746 | Servier-1
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1448525-91-4
-
Formula Weight747.289
-
Molecular FormulaC43H43ClN4O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (267.64 mM)
-
SMILESO=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9.Cl
-
Chemical NameN-(4-Hydroxyphenyl)-3-[6-[(3S)-3-(morpholinomethyl)-3,4-dihydro-1H-isoquinoline2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Casara P, et al. Oncotarget. 2018 Apr 13;9(28):20075-20088.
molnova catalog
related products
-
HA14-1
HA14-1 a small molecule, nonpeptidic Bcl-2 antagonist that binds Bcl-2 surface pocket with binding IC50 of 9 uM.
-
Obatoclax
A potent inhibitor of Bcl-2 family with IC50s of 1-7 uM for Bcl-2, Bcl-XL, Bcl-w, Bcl-B, Mcl-1 and Bfl-1.
-
Gossypol acetic acid
Gossypol acetic acid ((±)-Gossypol acetic acid) is a natural phenol that permeates cells and acts as an inhibitor.
Cart
sales@molnova.com